Bredberg U, Eyjolfsdottir G S, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V
Eur J Clin Pharmacol. 1986;30(1):75-7. doi: 10.1007/BF00614199.
Five healthy men were given 1.0 mg methysergide maleate intravenously and 2.7 mg methysergide maleate orally in a cross-over study. The systemic availability of methysergide was only 13%, most probably due to a high degree of first-pass metabolism to methylergometrine. We also found evidence of extrahepatic clearance of methysergide. After oral administration the plasma concentrations of the metabolite were considerably higher than those of the parent drug and the area under the plasma concentration curve (AUC) for methylergometrine was more than ten times greater than for methysergide. Our findings may be relevant to the treatment of migraine if methylergometrine contributes to the effect of methysergide. Methylergometrine had a significantly longer elimination half-life than methysergide (223 +/- 43 min vs 62.0 +/- 8.3 min and 174 +/- 35 min vs 44.8 +/- 8.1 min in the oral and intravenous studies respectively).
在一项交叉研究中,对5名健康男性静脉注射1.0毫克马来酸美西麦角,并口服2.7毫克马来酸美西麦角。美西麦角的全身可用性仅为13%,很可能是由于其高度首过代谢为甲基麦角新碱。我们还发现了美西麦角肝外清除的证据。口服给药后,代谢物的血浆浓度明显高于母体药物,甲基麦角新碱的血浆浓度曲线下面积(AUC)比美西麦角大十多倍。如果甲基麦角新碱有助于美西麦角的疗效,我们的发现可能与偏头痛治疗相关。甲基麦角新碱的消除半衰期明显长于美西麦角(口服和静脉研究中分别为223±43分钟对62.0±8.3分钟和174±35分钟对 44.8±8.1分钟)。